ClinicalTrials.gg
RecruitingNCT04521699CalmiGoUpdated May 5, 2026

Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.

An interventional study of CalmioGO Stress management device in Myocardial Infarction, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Myocardial Infarction by Mayo Clinic — 5 open to participants now, 6 under way, none of them phase 3. Myocardial Infarction · Mayo Clinic.

Planned enrollment
7th of 11
100 · median 107
Started
2022
with 2 others
No phase
7 of 19
3 open now
Registered
15th of 19
by date

Among the 19 studies in Myocardial Infarction by Mayo Clinic, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 with no phase, and was the 15th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

5 of the 19 studies in Myocardial Infarction by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myocardial Infarction by Mayo Clinic, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine if there are significant differences with respect to baseline between those randomized to CGo and standard-of-care versus standard-of-care alone after completing 12-weeks of therapy in terms of peripheral endothelial function measured by EndoPAT.

Read the detailed description

100 patients who have recently had an acute Myocardial Infarction ( heart attack) and are under going clinically indicated cardiac rehabilitation will undergo baseline testing including EndoPAT testing, mental stress testing, blood tests for cardiovascular disease biomarkers , physical assessments \& survey questionnaires. Patients then will be randomized to either CalmioGO stress management device + standard of care treatment or just standard of care treatment. Those randomized to CalmiGO stress management device treatment will be instructed to use the hand device much like an inhaler once a day for 12 weeks. After 12 weeks of rehabilitation both groups will return for reassessment of baseline tests.

03

Conditions studied

  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Ability to use the CamliGo device for 12-weeks
  • Willingness to complete study questionnaires, blood tests,\& EndoPat testing at the beginning and end of study
  • Patients who have had a recent MI who will be undergoing clinically indicated Cardiac Rehabilitation
  • Patients who have had a coronary or structural intervention performed in the cardiac catheterization laboratory within the last month, including: coronary stenting; coronary balloon angioplasty; transcatheter aortic valve replacement; mitral valve interventions; patent foramen ovale closures; alcohol septal ablation; paravalvular leak closure.
  • Patients being seen in the Chest Pain Clinic for Atypical chest pain

Exclusion criteria

Exclusion Criteria:

  • Cognitively impaired patients
  • Patient with Bipolar disorder, psychosis or delusional disorder
  • History of substance abuse or dependence
  • History of suicidality
  • Unstable cardiovascular or pulmonary disease
  • History of seizures
  • Latex allergy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    CalmioGo + Standard of care

    Use of CalmiGO stress management device once daily + standard of care during the 12 weeks of Cardiac rehabilitation

    Device: CalmioGO Stress management device

  • No intervention
    Standard of Care

    Stand of care alone with 12 weeks of Cardiac rehabilitation

Interventions

  • DeviceCalmioGO Stress management device

    CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.

06

What researchers measure

Primary outcomes

  1. Peripheral endothelial function

    Measurements made at baseline will be significantly different between those randomized to CalmioGo + standard of care to those receiving only standard of care treatment

    Time frame: 16 weeks

Secondary outcomes

  1. Physical assessments, cardiovascular disease biomarker blood tests as well resilience, joy, gratitude, mindfulness, health behavior , overall quality of life & perceived stress.

    Measurements made at baseline will be significantly different between those randomized to CalmiGo + standard of care then those to just standard of care.

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2026, 59 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 59 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2020
First posted
Aug 20, 2020
StartActual
Jan 13, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04521699
Lead sponsor
Mayo Clinic
Collaborators
CalmiGO
Responsible party
Valentina Nardi (Dr. Valentina Nardi, Mayo Clinic) — Principal investigator
First posted
Aug 20, 2020
Start date
Jan 13, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 5, 2026

Study contacts

Anna Pick
Contact
pick.anna@mayo.edu
507-255-0630
Diana Albers
Contact
Albers.Diana2@mayo.edu
507-255-6884
Valentina Nardi, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion